Somatic mutations in HER2 are detected in approximately 2%–5% of primary breast cancer patients, mostly as HER2 nonamplification,4 and treatment with neratinib or pyrotinib is a suitable option for this population. This evidence concerns the gene ERBB2 and breast carcinoma.